Understanding breast cancer subtypes in Black women
Understanding breast cancer subtypes in Black women
批准号:
9102023
负责人:
Maureen Sanderson
金额:
$7.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-07-01 至 2018-06-30
关键词:
AddressAgeAge at MenarcheBreastBreast Cancer Risk FactorBreast FeedingCancer EtiologyCase-Control StudiesCessation of lifeClassificationClinicalCollectionContraceptive UsageDevelopmentDiagnosisDiseaseEpidermal Growth Factor ReceptorEstrogen ReceptorsEtiologyFactor AnalysisFluorescent in Situ HybridizationFutureGene Expression ProfilingHealthHormone ReceptorHormone replacement therapyHormonesHumanImmunohistochemistryIncidenceKnowledgeMalignant NeoplasmsMammary NeoplasmsMenopauseModelingObesityOral ContraceptivesOutcomeParticipantPhysical activityProcessProgesterone ReceptorsRaceReportingRiskRisk FactorsSouth CarolinaSpecimenStagingTennesseeTerm BirthTissue SampleTumor MarkersTumor SubtypeTumor TissueWomanage groupbasecancer diagnosiscancer subtypesexperienceimmunohistochemical markersmalignant breast neoplasmmodifiable riskmolecular subtypesmortalityoutcome forecastparitypopulation basedracial differencescreeningtriple-negative invasive breast carcinoma
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Little is understood about what factors might explain why Black women tend to be diagnosed with more aggressive disease than White women. Based on characterization by immunohistochemical (IHC) markers, in every age group, White women have the highest rates of estrogen receptor (ER)+ breast cancer and Black women have the highest rates of ER- breast cancer. Moreover, triple negative breast cancer [TNBC; ER-, progesterone receptor (PR)-, human epidermal growth factor receptor 2 (HER2)-], an aggressive subset of basal-like breast cancer, is more common among Black women than among White women and has a worse prognosis than other subtypes. Recent studies, conducted largely among White women, have reported differences in risk by breast cancer subtype associated with hormone-related and other risk factors, such as age at menarche, oral contraceptive use, parity, age at first full-term birth, breastfeeding, age at menopause, hormone replacement therapy use, obesity and physical activity, suggesting that subtypes of breast tumors may have distinct etiologies. Few breast cancer studies have included large numbers of Black women, despite known marked racial differences in cancer incidence by subtype, and most studies did not collect tumor tissue to allow for detailed characterization of tumor subtypes.
To address this issue, we propose to collect tumor tissue specimens from 710 Black breast cancer cases, to classify breast tumors by hormone-receptor status, and to examine associations between hormone-related and other risk factors and breast cancer subtypes among Black women. The association of breast cancer with many modifiable risk factors appears to differ by tumor subtype; therefore, it is essential to perform subtyping of all breast tumors in future studies. The utilization of a soon to be completed population-based case-control study of Black women is a highly efficient approach to the collection and classification of
breast cancer tumor tissue since we have already obtained participants' permission. This proposed project will be one of the most comprehensive and well-powered studies to investigate the associations between hormone-related and other risk factors and breast cancer subtypes among Black women. Moreover, the collection of tumor tissue will provide immediate future opportunities to extend these risk factor analyses to intrinsic molecular subtypes. The results of this study will fill an important gap in current knowledge regarding assessment of hormone-related factors that increase risk for aggressive breast cancer among Black women, and will assist in delineating Black women at high (or low) risk for breast cancer subtypes with a poor prognosis who will most benefit from screening, and may provide new targets to reduce the risk of aggressive breast cancer among Black women. This may pave the way for the development of clinically useful breast cancer prediction models specific to race and breast cancer subtype.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Increasing HPV Vaccine Utilization Among African-Amerian Girls Through Social...
-
批准号:8534735
-
项目类别:
-
资助金额:$4.36万
-
财政年份:2013
-
负责人:Maureen Sanderson
-
依托单位:
A Multi-Center Epidemiologic Study of Breast Cancer In African American Women
-
批准号:8534733
-
项目类别:
-
资助金额:$10.41万
-
财政年份:2013
-
负责人:Maureen Sanderson
-
依托单位:
Increasing HPV Vaccine Utilization Among African-Amerian Girls Through Social...
-
批准号:8261514
-
项目类别:
-
资助金额:$5.08万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Practice Core
-
批准号:10493443
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
RESEARCH DESIGN, BIOSTATISTICS AND CLINICAL RESEARCH ETHICS
-
批准号:8359879
-
项目类别:
-
资助金额:$19.88万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Development: Cancer Outreach Core
-
批准号:8340678
-
项目类别:
-
资助金额:$5.14万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
A Multi-Center Epidemiologic Study of Breast Cancer In African American Women
-
批准号:8261510
-
项目类别:
-
资助金额:$11.67万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Practice Core
-
批准号:10705109
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Practice Core
-
批准号:10327941
-
项目类别:
-
资助金额:$29.38万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Project 1 BRAVE Strategy (Breast cancer Risk Assessment, achieVing Equity)
-
批准号:10327933
-
项目类别:
-
资助金额:$5.09万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Project 1 BRAVE Strategy (Breast cancer Risk Assessment, achieVing Equity)
-
批准号:10705092
-
项目类别:
-
资助金额:$5.6万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Developing Personalized Smoking Treatment in the Southern Community Cohort Study
-
批准号:10012766
-
项目类别:
-
资助金额:$2.91万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Cancer Outreach Core
-
批准号:10012764
-
项目类别:
-
资助金额:$5.59万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Project 1 BRAVE Strategy (Breast cancer Risk Assessment, achieVing Equity)
-
批准号:10493420
-
项目类别:
-
资助金额:$5.31万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Clinical Trials, Translational Pathology, Biostatistics and Bioinformatics Cores
-
批准号:10012765
-
项目类别:
-
资助金额:$50.32万
-
财政年份:2011
-
负责人:Maureen Sanderson
-
依托单位:
Priority Setting
-
批准号:8181480
-
项目类别:
-
资助金额:$2.46万
-
财政年份:2010
-
负责人:Maureen Sanderson
-
依托单位:
RESEARCH DESIGN, BIOSTATISTICS AND CLINICAL RESEARCH ETHICS
-
批准号:8173603
-
项目类别:
-
资助金额:$20.12万
-
财政年份:2010
-
负责人:Maureen Sanderson
-
依托单位:
Pilot1: Developing Tailored Intervention Address Differing Needs Cancer Survivors
-
批准号:8181489
-
项目类别:
-
资助金额:$6.51万
-
财政年份:2010
-
负责人:Maureen Sanderson
-
依托单位:
Pilot Project 3: To be Developed - Intervention
-
批准号:8181497
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2010
-
负责人:Maureen Sanderson
-
依托单位:
Core--Training
-
批准号:6726469
-
项目类别:
-
资助金额:$12.13万
-
财政年份:2003
-
负责人:Maureen Sanderson
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: